Evidence map›Paper›PMID 35670929›Full record

ArticleMolecular biology reports2022

A nucleotide signature for the identification of Pinelliae Rhizoma (Banxia) and its products.

Tianyi Zhang, Fusheng Xu, Markus Ruhsam, Li Feng, Miao Zhang, Zhengwei Wang, Xumei Wang

Abstract read
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Rapid authentication of endangeredFrontiers in plant science · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tianyi Zhang *School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, China.
Fusheng Xu *School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, China.
Markus RuhsamRoyal Botanic Garden Edinburgh, Edinburgh, EH3 5LR, UK.
Li FengSchool of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, China.
Miao ZhangLixian Spring Pharmaceutical Co. Ltd., Longnan, 742200, China.
Zhengwei WangShanghai Chenshan Botanical Garden, Shanghai, 201602, China.
Xumei WangSchool of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, China. wangxumei@mail.xjtu.edu.cn.

Funding

National Natural Science Foundation of China No. 31770364Natural Science Foundation of Shaanxi Province of China 2020JZ-05Scientific Research Supporting Project for New Teacher of Xi'an Jiaotong University No. 1191319801
6 · The paper itself

Abstract

backgroundEnsuring the authenticity of raw materials is a key step prior to producing Chinese patent medicines. Pinellia ternata (Thunb.) Breit. is the botanical origin of Pinelliae Rhizoma (Banxia), a traditional Chinese medicine used to treat cough, insomnia, nausea, inflammation, epilepsy, and so on. Unfortunately, authentic Pinelliae Rhizoma is often adulterated by morphologically indistinguishable plant material due to the insufficient regulatory procedures of processed medicinal plant products. Thus, it is important to develop a molecular assay based on species-specific nucleotide signatures and primers to efficiently distinguish authentic Pinelliae Rhizoma from its adulterants. METHODS AND

resultsThe ITS2 region of 67 Pinelliae Rhizoma and its common adulterants were sequenced. Eight single nucleotide polymorphisms within a 28-43 bp stretch of ITS2 were used to develop six primer pairs to amplify these species-specific regions. We assayed 56 Pinelliae Rhizoma products sold on the Chinese market, including medicinal slices, powder and Chinese patent medicines, which revealed that about 66% of products were adulterated. The most common adulterants were Pinellia pedatisecta (found in 57% of the assayed products), Arisaema erubescens (9%), Typhonium giganteum (2%) and Typhonium flagelliforme (2%).

conclusionsA severe adulteration condition was revealed in the traditional medicine market. The species-specific nucleotide assays developed in this study can be applied to reliably identify Pinelliae Rhizoma and its adulterants, aiding in the authentication and quality control of processed products on the herbal market.

Indexed as

Drugs, Chinese HerbalPinelliaNonprescription DrugsNucleotidesRhizomeDrugs, Chinese HerbalNonprescription DrugsNucleotidesChinese patent medicineDegraded DNAIdentificationNucleotide signaturePinellia ternata

Identifiers

PMID35670929
PMCPMC9171473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.